CZC54252 overcomes Osimertinib resistance by targeting EGFR C797S mutations in NSCLC
CZC54252 overcomes Osimertinib resistance by targeting EGFR C797S mutations in NSCLC
The introduction of EGFR inhibitors has revolutionized the management of NSCLC, leading to a significant extension of survival in the target patient population. Unfortunately, acquired resistance appears to be unavoidable, which restricts the use of EGFR‑TKIs in the clinic. EGFR^C797S represents a novel resistant mutation after treatment with the latest generation of EGFR inhibitor Osimertinib. Consequently, developing next‑generation EGFR‑TKIs targeting such resistant mutations is strongly demanded. ...These data indicate that CZC54252 represents a promising lead compound for overcoming Osimertinib resistance by targeting EGFR^C797S, which provides a chemical basis for the development of novel fourth‑generation EGFR inhibitors.
The emergence of EGFR C797S triple mutations as a common mechanism of acquired resistance to third‑generation EGFR inhibitors, such as Osimertinib, poses a major therapeutic challenge in NSCLC. Identifying a compound that can specifically target these mutations provides a critical step toward a clinically viable fourth‑generation inhibitor that can restore efficacy in patients whose tumors have progressed on Osimertinib.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT